Expanded Access Program for Tovorafenib (DAY101) in Patients with RAF-Altered, Relapsed or Hard-to-Treat Low-Grade Glioma | Clinical Trial

Expanded Access Program for Tovorafenib (DAY101) in Patients with RAF-Altered, Relapsed or Hard-to-Treat Low-Grade Glioma | Clinical Trial | Right2Hope